Search Results - "Moore, Von R"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Veterans Health Administration: Implementation of pharmacogenomic clinical decision support with statin medications and the SLCO1B1 gene as an exemplar by Tomcsanyi, Kelly M, Tran, Kelvin A, Bates, Jill, Cunningham, Francesca E, Silverman, Robert, Norris, Amy K, Moore, Von R, Voora, Deepak

    Published in American journal of health-system pharmacy (04-08-2023)
    “…Abstract Purpose To describe the implementation of clinical decision support tools for alerting prescribers of actionable drug-gene interactions in the…”
    Get full text
    Journal Article
  2. 2

    Comparison of hospitalization costs for the same adverse reaction associated with different medications by Alabbas, Sama A, Jiang, Rong, Au, Anthony, Vu, Michelle, Moore, Von R, Cunningham, Francesca E, Stroupe, Kevin, Bounthavong, Mark, Glassman, Peter A, Good, Chester B, Salone, Cedric, Aspinall, Sherrie L

    Published in American journal of health-system pharmacy (07-06-2023)
    “…Costs of hospitalization due to severe adverse drug reactions (ADRs) were previously estimated within the Veterans Health Administration (VHA), but additional…”
    Get full text
    Journal Article
  3. 3

    Interventions to Increase Leukocyte Testing during Treatment with Dimethyl Fumarate by Heidenreich, Paul A., Lin, Shoutzu, Gholami, Parisa, Moore, Von R., Burk, Muriel L., Glassman, Peter A., Cunningham, Francesca E., Sahay, Anju

    “…Dimethyl fumarate (DMF), a treatment for multiple sclerosis, may cause leukopenia and infection. Accordingly, periodic white blood cell (WBC) monitoring is…”
    Get full text
    Journal Article
  4. 4

    Adverse drug reactions in the Veterans Affairs healthcare system: Frequency, severity, and causative medications analyzed by patient age by Moore, Von R, Glassman, Peter A, Au, Anthony, Good, Chester B, Leadholm, Thomas C, Cunningham, Francesca E

    Published in American journal of health-system pharmacy (09-02-2019)
    “…Abstract Purpose Adverse drug events (ADEs) in the U.S. Department of Veterans Affairs (VA) were evaluated, and differences in age group report rates and…”
    Get full text
    Journal Article
  5. 5

    Reporting of adverse drug events in the Veterans Health Administration for patients whose treatment with empagliflozin or apixaban was discontinued by Fina, Paul M, Cunningham, Francesca E, Zhao, Xinhua, Glassman, Peter A, Moore, Von R, Au, Anthony, Aspinall, Sherrie L

    Published in American journal of health-system pharmacy (01-01-2020)
    “…To examine the reporting rates of adverse drug events (ADEs) with apixaban and empagliflozin as reports move up to the next level of spontaneous reporting…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Detection of potential look-alike/sound-alike medication errors using Veterans Affairs administrative databases by Zacher, Jessica M, Cunningham, Francesca E, Zhao, Xinhua, Burk, Muriel L, Moore, Von R, Good, Chester B, Glassman, Peter A, Aspinall, Sherrie L

    Published in American journal of health-system pharmacy (01-10-2018)
    “…PURPOSEResults of a study to estimate the prevalence of look-alike/sound-alike (LASA) medication errors through analysis of Veterans Affairs (VA)…”
    Get full text
    Journal Article
  8. 8
  9. 9